A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain

Acta Psychiatrica Scandinavica

Volumn 115, Issue 2, 2007, Pages 101-105

  Henderson, D C ^a,b   Fan, X ^a   Copeland, P M ^a   Borba, C P ^a   Daley, T B ^a   Nguyen, D D ^a   Zhang, H ^a   Hayden, D ^a   Freudenreich, O ^a   Cather, C ^a   Evins, A E ^a   Goff, D C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Freedom Trail Clinic   (United States)

Author keywords

Clozapine; Lipids; Schizophrenia; Sibutramine; Weight

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; SIBUTRAMINE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; EDUCATION; ETHNICITY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTHROPOMETRY; ANTIPSYCHOTIC AGENTS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CLOZAPINE; CYCLOBUTANES; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBINS; HUMANS; MALE; OBESITY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33846321605     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00855.x     Document Type: Article

References (15)

1. KANE J, HONIGFELD G, SINGER J, MELTZER H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
2. HENDERSON DC, CAGLIERO E, GRAY C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a fiveyear naturalistic study. Am J Psychiatry 2000;157:975-981.
3. HENDERSON DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62(suppl. 27):10-14; discussion 40-1.
4. LAMBERT M, HARO JM, NOVICK D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-243.
5. PATON C, ESOP R, YOUNG C, TAYLOR D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305.
6. PI-SUNYER FX. The medical risks of obesity. Obes Surg 2002;12(suppl. 1):6S-11S.
7. FAULKNER G, SOUNDY AA, LLOYD K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-332.
8. HENDERSON DC, KUNKEL L, NGUYEN DD, DALEY TB, LOUIE PM, GOFF DC. Aripiprazole as an adjunct to clozapine therapy in chronic schizophrenics. Acta Psychiat Scand 2006; 113: 142-147.
9. GLAZER G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814-1824.
10. FINER N. Present and future pharmacological approaches. Brit Med Bull 1997;52:409-432.
11. WEINTRAUB M, RUBIO A, GOLIK A, BYRNE L, SCHEINBAUM M. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-337.
12. HENDERSON DC, COPELAND PM, DALEY TB et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-962.
13. SPITZER RLWJ, GIBBON M, FIRST MB. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992;49:624-629.
14. BYMASTER F, CALLIGARO DO, FALCONE JF et al. Radioreceptor binding profile of the atypical antipsychotic drug. Neuropsychopharmacology 1996;14:87-96.
15. MILLAN MJ, SCHREIBER R, DEKEYNE A et al. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin- 3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 1998;286:1356-1373.